High Return Stocks

Finding Tomorrow’s Winners Today using charts, screeners and other various trading enablement tools.

recent posts

    • Oracle ($ORCL) — Why This Pullback Could Be a Good Buy Opportunity

      Oracle ($ORCL) — Why This Pullback Could Be a Good Buy Opportunity

      I am buying into $ORCL this morning in the $188 range for a long swing going into 2026. Many analyst have it in the mid $300’s on their targets indicating we are trading at a very discounted rate on the big drop today. They saw an EPS beat and strong cloud/AI growth which I believe will continue to help their overall revenues and profitability.
      Despite the sharp pullback, Oracle still shows several compelling bullish indicators worth highlighting. Cloud momentum remains strong with OCI and SaaS delivering some of the fastest growth rates in enterprise software, and the company’s massive $500B+ backlog provides multi-year revenue visibility that few tech peers can match. Earnings strength—particularly on the bottom line—suggests long-term margin expansion as large AI and cloud contracts scale. Technically, the stock is approaching oversold conditions, sitting near multi-month support with volume capitulation that often precedes a rebound. That said, investors should also acknowledge a few bearish factors: the recent revenue miss, elevated capex, and rising leverage all create short-term pressure and headline risk. While these concerns explain the volatility, they don’t invalidate the broader growth trajectory, making the current dip a potentially attractive entry point for long-term buyers who manage risk appropriately.

    • ($CLPS): Profitable Growth, Global Hiring, and AI-Powered Modernization

      ($CLPS): Profitable Growth, Global Hiring, and AI-Powered Modernization

      In the crowded world of fintech and IT services, most small-cap companies struggle to differentiate themselves. CLPS Incorporation (NASDAQ: CLPS) is starting to stand out. Between its profitable earnings this year, aggressive global hiring, and a landmark AI-powered banking modernization project, CLPS is signaling that it’s positioned for growth in one of the most important transformation markets worldwide. Do note this is a a higher risk trade as it is close to $1.00 right now, which I believe is very low with all the positive news coming out. They are compliant with NASDAQ and do have cash in the bank for operating.

      Profitable Earnings Signal Stability

      In 2025, CLPS reported a profitable earnings result — a key milestone for a micro-cap technology company. Many small service providers operate at a loss for years while trying to scale. CLPS has shown it can manage costs, deliver projects efficiently, and still finish in the black.

      This profitability not only validates the business model but also strengthens confidence that CLPS can fund expansion without relying solely on dilutive financing.

      LinkedIn Hiring Surge Points to Global Demand

      One of the strongest signals of momentum is CLPS’s hiring activity. On LinkedIn, the company has been expanding its workforce rapidly across geographies, from Asia to North America.

      • New roles in AI development, fintech system modernization, and cloud architecture have been posted and filled.
      • Hiring at this scale reflects growing demand for CLPS’s services from financial institutions globally.
      • This trend suggests the company is not just sustaining business, but it’s scaling aggressively to capture new clients.

      PR Spotlight: Modernizing a Major Hong Kong Bank With AI

      This month, CLPS announced a major project with a leading Hong Kong bank, showcasing its ability to bring AI into real-world system modernization:

      • Transformed a 30-year-old mortgage system with more than 1,500 components (VB programs, MS Access databases, COBOL jobs, etc.).
      • Achieved a 70% automation rate in code conversion using AI tools, including Microsoft Copilot.
      • Delivered the project in 7 months with ~20 developers, compared to the industry norm of 24 months and 40–50 developers.
      • Migrated the bank to a modern Java/React/PostgreSQL cloud stack, cutting costs and improving scalability.

      This case proves that CLPS can execute complex, high-stakes projects using AI and it provides a repeatable model for other institutions facing the same legacy code challenges.

      Why This Matters

      1. Profitable Operations → CLPS isn’t just surviving; it’s delivering earnings, which reduces financial risk for investors.
      2. Hiring = Growth → Expanding headcount worldwide signals strong demand and confidence in future deal flow.
      3. AI Differentiation → Unlike traditional outsourcing firms, CLPS has proven it can leverage AI to shorten timelines and reduce costs, which banks and enterprises urgently need.
      4. Repeatable Playbook → Thousands of banks and corporations still run outdated systems, CLPS now has a tested framework to modernize them.

      Investor Takeaway

      CLPS has crossed into a rare combination for a small-cap tech company: profitability, global expansion, and innovative delivery methods.

      • The profitable earnings report anchors its financial health.
      • The hiring surge highlights accelerating demand.
      • The Hong Kong bank project validates its ability to execute at scale using AI.

      For investors seeking exposure to AI + financial system modernization in a small-cap with global ambitions, CLPS may be an a hidden opportunity worth tracking closely.

    • Will be posting again in a week or two

      Will be posting again in a week or two

      Hi Everyone, sorry for no new blogs the past week. We had water damage to our home and have been dealing with insurance, contractors, remediators, etc with not a lot of time to make new posts. That being said a lot of small cap companies seem to be emerging and look to be good plays for the coming months. I highly recommend using finviz screener to search for small caps that have low debt and are sitting above moving averages https://finviz.com/screener.ashx . If you are unfamiliar with how to use finviz, here is a good guide https://finviz.com/help/screener.ashx . Will be back soon! Hope everyone has been enjoying these blogs.

    • MannKind ($MNKD): Analyst Targets Are Rising — Should you wait for things to cool off?

      MannKind ($MNKD): Analyst Targets Are Rising — Should you wait for things to cool off?

      MannKind Corp. (NASDAQ: MNKD) just experienced a major surge, with shares jumping more than 20% intraday on heavy volume. The rally has been fueled by a wave of analyst upgrades, positive trial data, and new strategic moves that could set the stage for long-term growth.

      But with the stock technically overbought in the short term maybe wait for the hype to cool off before adding to your positions. I will be watching for a better entry point once the volume settles down hopefully in the low $5 range.

      📈 Analysts Are Getting Bullish

      Wall Street is turning more optimistic on MannKind:

      • H.C. Wainwright: Reiterated a Buy rating with an $11 target.
      • Wedbush: Reaffirmed a Buy with the same $11 target.
      • RBC Capital: Raised its price target from $7 → $8, keeping an Outperform rating.

      Consensus targets cluster around $9–$11 per share, implying ~60–100% upside from current levels.

      What’s Driving the Optimism?

      1. Pipeline Strength
        • Promising trial results for Tyvaso and Afrezza derivatives.
        • Advancing treatments for idiopathic pulmonary fibrosis, NTM, and other lung/cardiometabolic diseases.
      2. Strategic Financing
        • Blackstone-backed financing provides non-dilutive capital.
        • Ensures MannKind has cash to support its growth strategy without over-burdening shareholders.
      3. Acquisition of scPharmaceuticals
        • Expands MannKind’s footprint into adjacent therapeutic areas.
        • Creates new revenue opportunities and strengthens its long-term growth story.

      Risks and Red Flags

      • Overbought Technicals: RSI above 80 and prices pressing against upper Bollinger Bands suggest MNKD is stretched in the short term.
      • Volatility: Biotech names are often highly volatile, especially after catalysts. Sharp pullbacks are common even within strong uptrends.
      • Execution Risk: Integration of scPharmaceuticals and future trial success will be key. A stumble could weigh on sentiment quickly.

      Investor Playbook

      MannKind looks attractive as a medium- to long-term growth story supported by bullish analyst targets, solid financial backing, and a promising pipeline.

      But after today’s spike, the smarter strategy may be patience:

      • Gradual Entry: Add slowly on pullbacks toward $5–$5.50 if momentum cools.
      • Risk Controls: Keep position sizes small—biotech remains a high-risk/high-reward sector.
      • Catalyst Monitoring: Watch for trial updates and integration progress with scPharma as key drivers.

      Bottom Line

      MannKind is back on Wall Street’s radar with a compelling mix of analyst support, strategic moves, and pipeline promise. While the long-term outlook is bullish, near-term technicals suggest waiting for a better entry point.

    • MongoDB ($MDB): A Compelling Growth Opportunity

      MongoDB ($MDB): A Compelling Growth Opportunity

      MongoDB is gaining renewed investor interest. The recent quarter revealed big cloud growth and upgraded guidance, while AI momentum continues to show future upside. They also added 2,600 new customers in Q1 an all time record in customer growth, showing their product and sales outreach is working. Average analyst price targets also show over 30% growth from current levels. I will be looking to slowly add in incase there is another dip down to the $205-$210 range, but things are looking to be turning around for $MDB.

      Why It Could Be a Great Investment Now

      1. Reaccelerating Revenue Growth & Upside Momentum

      2. AI Tailwinds & Strategic Positioning

      3. Technical Signals Turning Favorable

      • IBD upgraded MongoDB’s Relative Strength (RS) Rating to 72 (from 65), signaling upward momentum—though a breakout above RS 80 remains a key technical milestoneInvestors.

      Analyst Average Target Price for MongoDB (MDB)

      Here’s what Wall Street analysts project for MDB’s 12-month price target:

      What to Watch Out For

      1. Pullback & Uncertain Earnings Headroom Ahead

      • Despite strength in cloud, MDB’s stock is down ~10.6% over the past month and roughly flat YTD, raising questions about renewed confidence ahead of earningsAskTraders.com.
      • Analysts expect Q2 EPS of ~$0.64–0.67 and revenue near $553 million—but earnings could be narrow even if revenue holds strong, pointing to margin pressureAskTraders.comTipRanks.

      2. Competitive and Macro Execution Risks

      • Although Atlas’s growth is impressive, non-Atlas segments remain challenged. Total net losses (e.g., $54.5M) underscore the balancing act between growth and profitabilityAInvest+1.
      • Broader factors, like tech sector regulation and shifting cloud spending, may temper adoption trends despite AI tailwindsAInvest.

    • 🎯 Nike ($NKE): Slowly Turning the Corner?

      🎯 Nike ($NKE): Slowly Turning the Corner?

      After a lengthy pull back, shares of Nike are finally starting to stabilize and for the first time in months, the technical picture is showing constructive signs. Especially looking at the moving averages and how $KNE is sitting above the 20, 50 and 200 day moving averages. $NKE also has an dividend date of Aug 30th, meaning we could see this walk up next week going into the dividend. For those looking to start a long term position this could be a great opportunity to start adding and even utilize covered calls to make additional money on your shares.

      🔧 Technical Setup

      Nike has reclaimed both its 20-day and 50-day moving averages, a positive momentum shift after spending most of 2024 below trend. The stock is now trading in the $77–78 range, and while it still faces a major resistance zone near $80, the price action has tightened and the short-term averages have started to slope upward.

      Key technical levels to watch:

      Price LevelDetails
      $74–76Strong near-term support
      $80Major resistance / breakout level
      $86–88Next resistance (if $80 is cleared)

      📌 A sustained close above $80 would confirm a trend reversal and open the door to a deeper recovery.

      🟢 Why it May Be a Good Time to Start Adding Slowly

      Nike hasn’t fully broken out yet, but the combination of improving short-term trend and rising volume near support suggests that smart money is accumulating. The idea here isn’t to go “all in,” but rather to start layering into a long-term position as confirmation builds.

      Reasons to consider accumulating:

      • Back above key moving averages = momentum shift
      • Valuation has reset after a ~35% pullback from 2021 highs
      • Price has held the $74 support on multiple tests
      • A break over $80 could trigger a larger move as technicians and algos re-enter

      🔮 Bullish Long-Term Case

      DriverDescription
      Emerging Market GrowthRobust expansion in China, India, and Latin America should help reaccelerate revenue in FY2026–27
      Direct-to-Consumer (DTC) MigrationNike now drives over 42% of revenue from DTC vs ~15% a decade ago — much higher margin
      New Product Cycles / InnovationRevamped basketball and running product lines, upcoming Olympics visibility, and women’s category strength
      Share BuybacksManagement still has ~$12B remaining on its repurchase authorization — providing downside support and EPS tailwind

      ⚠️ Key Risks

      RiskDetail
      Consumer WeaknessStill seeing softness in North America — any deterioration could stall the turnaround
      China VolatilityMacro headwinds or geopolitical tensions could slow growth in its largest international market
      ValuationEven after the decline, NKE still trades near 30x forward EPS, higher than most retail peers
      Failure to Reclaim $80A rejection at major resistance could bring the stock back to the $72–73 range

      ✅ Bottom Line

      Nike isn’t a momentum play yet — but it is starting to look like a high-quality long-term name that is coming back into favor.
      For long-term investors, starting a small position while it holds above the moving averages and building on strength through $80 offers a very reasonable risk-reward setup.

    • $TGT looking bullish bounced off 200 Month MA

      $TGT looking bullish bounced off 200 Month MA

      $TGT is beginning to look attractive at current levels, with prices recently bouncing off 200 month moving average, shows there is a good support level that has formed. Trading much lower than counterparts like Walmart $WMT. I’ve added $TGT to my watchlist, Target is attractive on valuation and income metrics, it is currently trading well below fair values suggested by both peer P/E and Morningstar modeling, and offering a stout 4.5% dividend yield. With Earnings bringing this much lower today, now may be a great time to start a position.

      Fundamentals & Value Proposition

      • Undervalued Compared to Peers: Target trades at a forward P/E of approximately 12.4×, substantially lower than peers such as Dollar General (~18×), Dollar Tree (~17×), and Costco (~51×) — suggesting potential value if fundamentals stabilize. fool.com+4nasdaq.com+4stockinvest.us+4
      • Undervalued on Morningstar Measures: Assigned a 4-star rating with a long-term fair value estimate near $123. morningstar.com
      • Dividend Appeal: Recent articles highlight a near-record 4.5% dividend yield, offering income support during the recovery. fool.com

      Near-Term Headwinds & Retail Footprints

      • Tariff Pressure & Cost Exposure: Roughly 50% of Target’s cost of goods sold comes from imports — much higher than Walmart (~33%) — meaning volatility from tariffs could force price increases of up to 8%, nearly double Walmart’s impact. marketwatch.com+1
      • Eroding Digital Traction: Mobile app usage dropped 14% in July, whereas Walmart’s surged 17% — signaling weak momentum in Target’s digital and marketplace strategy. barrons.com+2marketwatch.com+2
      • Retail Foot Traffic and Brand Loyalty Decline: In-store experience issues, rollback of DEI policies, and customer dissatisfaction have combined to drive traffic down and erode brand perception. morningstar.com+7businessinsider.com+7apnews.com+7
      • Retail Partnership Disruption: The end of its Ulta Beauty “shop-in-shop” features (600+ locations by 2026) removes a premium beauty draw that had supported Target’s discretionary success. fool.com+4the-sun.com+4marketwatch.com+4

      Technical Overview

      • Positive Technical Setup: Target shows buy signals from both short- and long-term moving averages, and the MACD indicator is also signaling upward momentum. Support levels appear around $104–$105, while risk lies if these are lost. stockinvest.us+2nasdaq.com+2

      Summary

      Target is attractive on valuation and income metrics — currently trading well below fair values suggested by both peer P/E and Morningstar modeling, and offering a stout 4.5% dividend yield. However, near-term risks are significant: increased tariff burden, weakening digital engagement, declining in-store experience, and the termination of its Ulta partnership all weigh on the turnaround narrative. While technicals hint at a potential stabilization, meaningful recovery will likely depend on strategic leadership, digital revitalization, and execution on cost efficiencies.

    • $INTC : Is Intel a good buy right now?

      $INTC : Is Intel a good buy right now?

      Hi Everyone, I hope you all are enjoying these posts. I was going to make this blog yesterday, but was too busy. Seems like Intel is already doing great today. I am keeping it on watch for a slight pullback from today’s hype as a future swing. Here is why, Intel is attracting serious institutional interest ( including a fresh $2 billion investment from SoftBank and a potential 10% equity stake from the U.S. government ) signaling an increased confidence in its long-term strategic turnaround and its central role in domestic chip manufacturing. At the same time, the stock is still trading near multi-year lows, giving investors an opportunity to buy into the recovery thesis before the foundry expansion and federal backing are fully priced in.

      1. SoftBank Investment as a Confidence Boost

      SoftBank is injecting $2 billion into Intel, buying a nearly 2% stake at $23 per share — a clear sign of confidence in Intel’s strategic comeback and U.S. semiconductor manufacturing. This move sparked a 4–6% rally upon announcement.TECHi+15Barron’s+15The Washington Post+15

      2. Potential U.S. Government Equity Stake

      There are reports that the U.S. government is considering converting part of Intel’s CHIPS Act funding (around $10.9 billion) into a 10% ownership stake, potentially making it a major anchor shareholder.Investors+6Reuters+6CRN+6 This could provide both strategic support and political backing.

      3. Strategic Momentum & Industry Alignment

      SoftBank’s ownership of Arm — a key player in chip design — suggests potential future collaboration. Combined with federal interest, these developments could facilitate recovery in Intel’s foundry ambitions and broader U.S. chip resurgence.Reuters+15Barron’s+15The Times of India+15

      Key Risks to Weigh

      Summary

      With renewed investor confidence via SoftBank’s $2B investment and the potential for a 10% U.S. government stake, Intel’s strategic outlook is looking brighter. Especially if you believe in its role in USA chip independence. However, investors need to consider the upfront downside risk from potential dilution and increased political oversight. Intel’s broader comeback still hinges on execution, if its foundry business and new leadership can deliver results, this could be a turnaround worth owning from this level. If not, the structural headwinds remain significant.

    • Novo Nordisk ($NVO) is Oversold!!!

      Novo Nordisk ($NVO) is Oversold!!!

      I believe $NVO is starting to bottom out. With nearly $67.5B in assets, $18.9B in cash, and a healthy 59% debt-to-equity ratio, it’s in a prime position to weather market swings and invest in future expansion. The company’s 3.2% dividend yield, coupled with a historically low P/E of around 12.9×, offers both income and potential value upside. Technically, NVO is holding key support in the $45–$48 range and could see upside toward $58, $64, and $79 if momentum continues. Long term, its projected $80B cash reserves by 2028 position it for major acquisitions that could reshape its market share. For investors seeking both steady returns and long-term growth catalysts, now may be a compelling time to keep NVO on the radar.

      Novo Nordisk (NYSE: NVO) has been one of the most closely watched pharmaceutical companies in recent years, thanks to its leadership in diabetes care, obesity treatment, and other chronic disease solutions.

      1. Leadership in Obesity & Diabetes Treatments

      Novo Nordisk’s GLP-1 drugs, such as Ozempic and Wegovy, have completely reshaped the obesity and diabetes market. Demand continues to outpace supply, with global interest expanding beyond the U.S. into Europe and Asia. This dominant position gives NVO a competitive moat that’s hard to match.

      1. Growing Market Potential

      The global obesity drug market is projected to grow into the hundreds of billions over the next decade. Novo Nordisk is positioned not just to participate in this growth, but to lead it. Their early-mover advantage and brand trust put them in an ideal spot to capture market share before competitors ramp up.

      1. Strong Financial Performance

      Recent earnings have shown revenue growth well above market expectations, powered by both rising prescription volumes and premium pricing. Healthy margins and consistent cash flow generation give the company flexibility for expansion, R&D, and shareholder returns.

      1. Expanding Beyond Obesity & Diabetes

      While most investors focus on its blockbuster weight-loss drugs, Novo Nordisk has a robust pipeline addressing other chronic diseases, including cardiovascular and kidney conditions. This diversification reduces risk and opens up multiple growth pathways.

      1. Long-Term Tailwinds

      With global health systems prioritizing preventative care and chronic disease management, demand for Novo Nordisk’s treatments should remain strong. Aging populations, rising obesity rates, and better insurance coverage worldwide all serve as long-term growth drivers.

      Summary Table

      AreaHighlight
      Financial Position~$67.5B in assets; $10.7B FCF; $18.9B cash; 59% debt/equity
      Dividends & Valuation~3.2% yield; P/E ~12.9×—substantially below long-term average
      Technical SetupSupport ~$45–48; Resistance ~$58, $64, $79
      Growth Strategy~$80B in cash reserves for strategic M&A opportunities by 2028
    • Why $APWC Could Be a Hidden Goldmine (Golden-cross Pattern Confirmed)

      Why $APWC Could Be a Hidden Goldmine (Golden-cross Pattern Confirmed)

      $APWC is another one of my top holds I have been accumulated this year. With earnings today coming out very positive and turning a net loss into a profit QoQ, this could be the next 100%-200% runner once volume comes pouring in. APWC also has a history of running very hard, for example in 2021 it ran from $1 range to $9 representing a 800% gain. There is also a golden cross chart pattern that just took place on the 1d candle ticker chart, furthering my bullish case.

      1. Undervalued Compared to Peers

      With a P/E ratio around 11x, APWC trades at a significant discount to the broader market, where typical P/Es are well above 20x Simply Wall St+1. This suggests investors may be overly cautious—and growth or stability could unlock upside.

      2. A Profitable Quarter Amid Trade Turmoil

      Q2 2025 delivered strong results:

      • Revenue: $126.9M (+26% QoQ, +11% YoY)
      • EPS: $0.03—up from losses in prior periods
        These show the company can turn corners and deliver through adversity MorningstarTipRanks.

      3. Strategic Cost Structure & Geographic Reach

      APWC benefits from a geographically diversified footprint and low-tariff manufacturing locations—offering pricing flexibility and supply chain resilience amid global trade tensions TipRanks.

      4. Enough Cash, Growing Efficiency

      Despite cash flow pressure in the quarter, the company maintains solid liquidity—$35M in cash—and shows improving operational efficiency, as evidenced by rising ROCE and strong FCF yield in recent years AInvestMorningstar.

      5. Sector Tailwinds in the APAC Region

      The wire and cable industry in Asia-Pacific is expected to grow at a 6.4% CAGR to $133B by 2032, driven by smart grid expansion, EV infrastructure, telecom upgrades, and renewable energy projects—offering a growing end-market for APWC Stellar Market Research.

      Risks to Watch

      1. Still Lagging Capital Efficiency
        Even with recent improvements, APWC’s ROCE (Return on Capital Employed) still lags the industry average by a wide margin AInvest.
      2. Liquidity & Execution Risk
        Operating cash flow dipped and trade receivables rose—pointing to near-term cash strain Morningstar.
        Plans for a rights offering could mean dilution—tempting if used for growth, risky if not executed well.
      3. Volatile Market and Limited Coverage
        The stock’s low liquidity and limited institutional analyst coverage (MarketBeat ranks it in the low 20th percentile for industrials) create uncertainty for investors MarketBeatStockInvest.

      Final Verdict: A Classic Underdog Story

      APWC may be flying under most investors’ radars, but the fundamentals point to a potential setup:

      • Strong recent results and disciplined strategy
      • Solid long-term growth tailwinds from APAC infrastructure and energy transitions
      • Undervalued relative to its peers, offering a potential value entry point

    High Return Stocks

    Finding Tomorrow’s Winners Today using charts, screeners and other various trading enablement tools.

    Skip to content ↓